Publications by authors named "Emilien Ezine"
Background: Although the PI3K/AKT/mTOR pathway is one of the most altered pathways in human tumours, therapies targeting this pathway have shown numerous adverse effects due to positive feedback paradoxically activating upstream signaling nodes. The somewhat limited clinical efficacy of these inhibitors calls for the development of novel and more effective approaches for targeting the PI3K pathway for therapeutic benefit in cancer.
Main Body: Recent studies have shown the central role of mTOR complex 2 (mTORC2) as a pro-tumourigenic factor of the PI3K/AKT/mTOR pathway in a number of cancers.
Article Synopsis
- The study aimed to investigate the cardiovascular immune-related adverse events (irAEs) linked to immune checkpoint inhibitors (ICIs) in cancer patients, as the risks and incidence of these events were not well understood.
- Researchers reviewed randomized clinical trials (RCTs) to analyze data on various cardiovascular adverse events (CVAEs), finding that ICI exposure significantly increased the risk of six specific CV irAEs, including myocarditis and dyslipidemia.
- The incidence of these cardiovascular events varied between 3.2 to 19.3 per 1000 patients, emphasizing the need for awareness among healthcare providers regarding these potential risks when using ICIs.
Chimeric-antigen-receptor T cells directed against CD19 (CAR-T) are emerging hematological therapeutics with scarce data on its overall safety profile spectrum. To determine the clinical features and incidence of adverse-drug reactions (ADR) associated with CAR-T. This observational, cross-sectional, pharmacovigilance cohort study examined individual case safety reports from the World Health Organization database VigiBase and meta-analysis of data from CAR-T trials and cohorts in the literature was also performed through March, 2020.
View Article and Find Full Text PDFBackground: Immune checkpoint inhibitors (ICIs) have significantly improved survival in advanced melanoma. There is a need for robust biomarkers to identify patients who do not respond. We analysed 14 baseline F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) metrics and their evolution to assess their correlation with patient outcome, compared with 7 established biological markers and 7 clinical variables.
View Article and Find Full Text PDFBackground: The risk of cardiovascular adverse events from rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors is not fully characterized.
Aim: To evaluate the cardiovascular adverse events risks related to BRAF and/or MEK inhibitors in randomized placebo-controlled clinical trials and in the real-life setting.
Methods: We used two approaches.